1. Home
  2. CFFI vs TLSI Comparison

CFFI vs TLSI Comparison

Compare CFFI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C&F Financial Corporation

CFFI

C&F Financial Corporation

N/A

Current Price

$77.60

Market Cap

251.2M

Sector

Finance

ML Signal

N/A

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.07

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFFI
TLSI
Founded
1927
2010
Country
United States
United States
Employees
N/A
102
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
251.2M
270.2M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
CFFI
TLSI
Price
$77.60
$4.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
5.7K
448.5K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
2.53%
N/A
EPS Growth
37.94
N/A
EPS
2.08
N/A
Revenue
$140,841,000.00
N/A
Revenue This Year
N/A
$35.45
Revenue Next Year
N/A
$37.58
P/E Ratio
$37.02
N/A
Revenue Growth
10.63
N/A
52 Week Low
$61.45
$2.20
52 Week High
$86.18
$7.95

Technical Indicators

Market Signals
Indicator
CFFI
TLSI
Relative Strength Index (RSI) 47.98 50.15
Support Level $68.17 $3.69
Resistance Level $78.93 $4.38
Average True Range (ATR) 2.49 0.34
MACD -0.64 -0.05
Stochastic Oscillator 11.82 33.06

Price Performance

Historical Comparison
CFFI
TLSI

About CFFI C&F Financial Corporation

C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: